Zolgensma
Generic name: onasemnogene abeparvovec
Manufactured by: Novartis
Therapeutic category: Gene Therapy
Tariff Status Explanation
This drug falls into a specialty category (orphan drug, gene therapy, plasma-derived, etc.) that is explicitly exempt from Section 232 tariffs.
Key Dates
Sept 29, 2026
Section 232 tariff effective for all other companies
April 2, 2030
Onshoring plan exemptions expire (revert to 100%)
What Can You Do?
- →Ask your doctor if a generic or biosimilar equivalent is available. Generics are fully exempt from all tariffs.
- →Check if your manufacturer has signed an MFN deal. View all MFN deals →
- →Use our Savings Guide to find discount programs, patient assistance, and alternatives before tariffs take effect.
Will Zolgensma Cost More Due to Tariffs?
Zolgensma (onasemnogene abeparvovec) is manufactured by Novartis and is classified as a gene therapy medication.
Remember that the tariff applies to the drug's acquisition cost — the price pharmacies pay to purchase the drug — not necessarily your final copay. Patients with insurance may see the tariff impact appear gradually through formulary changes or premium increases. Uninsured patients and those paying cash prices may see more direct impacts.